<DOC>
	<DOCNO>NCT00561171</DOCNO>
	<brief_summary>This phase II , double-blind , randomize , parallel-design , four-week study investigate efficacy , safety tolerability two different dos SPP635 type II diabetic patient mild moderate hypertension albuminuria . The total study duration patient complete entire study approximately 7 week include 2 week Screening Phase , 1 week Wash-out Phase , 4 week Treatment Phase 1 week Follow-up Phase . All treatment certain antihypertensive drug ( washed-out ) effect BP antidiabetic treatment must keep stable dose whole study . A maximum 50 patient total plan enrol .</brief_summary>
	<brief_title>Phase IIa Study Investigate Efficacy Safety SPP635 Diabetic Hypertensive Patients With Albuminuria</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Albuminuria</mesh_term>
	<criteria>men woman , 18 75 year hypertension diabetes mellitus type II albuminuria donation blood past month significant illness history malignancy Heart failure , stroke , myocardial infarction , transient ischaemic attack , hypertensive encephalopathy within past 6 month Current past history clinically significant electrocardiogram ( ECG ) abnormalities permanent 2nd degree atrioventricular ( AV ) block high , unstable angina , percutaneous transluminal coronary angioplasty ( PTCA ) , coronary artery bypass graft ( CABG ) cerebrovascular accident last three month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2008</verification_date>
</DOC>